Compare Cassava Sciences Inc (FLNA) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares MBS ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while iShares MBS ETF trades at $93.7. The key difference: iShares MBS ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MBB | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $96.91 |
52-Week Low | $1.09 | $92.62 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
The iShares MBS ETF (MBB) trades at $93.665, showing minimal daily movement with a slight decline of 0.01%. Technical indicators present a bearish bias, with moving averages signaling selling pressure and oscillators in neutral territory. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced holdings. The ETF maintains a consistent dividend distribution schedule, with recent payments around $0.33 per share.
As a mortgage-backed securities ETF, MBB offers exposure to the U.S. housing debt market with monthly dividend distributions. The fund faces interest rate sensitivity and prepayment risks inherent to MBS investments. While providing diversification within real estate fixed income, investors should monitor Federal Reserve policy and housing market trends that directly impact underlying security performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
